Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Date of Report: February 21, 2014
Event Date: February 21, 2014 (Amendment execution); February 27, 2014 (Press release)
Novavax, Inc. entered into an amendment to its Prime Contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS BARDA).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than financial performance results.
Material Changes
- Contract Extension: The Amendment extends the base period of performance under the Prime Contract with HHS BARDA to September 23, 2014.
- Contract Terms: The remainder of the Prime Contract remains unchanged.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on February 27, 2014, announcing the transaction. The full text of the Amendment is referenced as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies arising from this amendment, noting only that the description is qualified by reference to the full Amendment document.
Investor Verification Checklist
- Verify the specific financial obligations and milestones associated with the extended performance period ending September 23, 2014, by reviewing the Amendment filed as an exhibit to the 2013 Form 10-K.
- Confirm the status of the Prime Contract with HHS BARDA and any potential impact on future revenue recognition.
- Review the press release dated February 27, 2014 (Exhibit 99.1) for additional context on the strategic importance of the extension.